Barclays has upgraded Thermo Fisher Scientific Inc (TMO) to Overweight from Equal-Weight, signaling a more favorable outlook for the company. This change, effective September 10, 2025, comes as Thermo Fisher continues to navigate the life sciences tools and services industry, where it plays a critical role in supporting the scientific community with innovative products and services.
Headquartered in Waltham, Massachusetts, Thermo Fisher employs 125,000 full-time staff and offers a comprehensive range of solutions through its various segments. The Life Sciences Solutions segment provides reagents, instruments, and consumables vital for medical research and drug development. The Analytical Instruments segment delivers essential tools and services across diverse applications, while the Specialty Diagnostics segment offers diagnostic test kits and reagents. Additionally, its Laboratory Products and Biopharma Services segment supplies nearly all laboratory needs, including purification and filtration technologies.
As of November 20, 2025, Thermo Fisher's market capitalization stands at $217.5 billion, with a P/E ratio of 33.13 and an EPS of 17.30. The company has a dividend yield of 30.0%. Upcoming earnings reports are scheduled for July 21, 2026, with an estimated EPS of $5.94 and revenue of $11.6 billion. This follows a solid Q3 2025 performance, where the company reported an EPS of $5.79, surpassing estimates by 4.4%.
Analyst consensus currently reflects a Buy rating, with 8 Strong Buy, 17 Buy, and 7 Hold ratings. This upgrade from Barclays underscores a renewed confidence in Thermo Fisher's strategic direction and operational fundamentals, which may catalyze further positive sentiment in the market.